30 closest matches · ranked by relevance
Type 1 Diabetes
Primary: Number of Severe Hypoglycemic Event - Cohort A — 0 events
Hearing Loss
Primary: Report on Degree of Hearing as Measured by Pure Tone Audiogram — 5; 2; 2; 0 participants
School Board Health Centers
Primary: Number of Enrolled Participants Who Attended SBHC — 127; 252 participants
Lower Limb Amputation Below Knee (Injury) · Lower Limb Amputation Above Knee (Injury) · Lower Limb Amputation Knee
Primary: Patient-perceived Mobility (PLUS-M)™ — 57.2; 56.9; 58.3; 57.6 units on a scale — p=0.286
Myopia
Primary: Visual Acuity (Investigational vs Air Optix Aqua Lens) — -0.050; -0.060; -0.034; -0.039 LogMAR
Atrial Septal Defect · Atrial Fibrillation · Atrial Arrhythmia
Primary: Physician Feedback on VERAFEYE System — 100; 100; 100; 100 percentage of participants
Fecal Incontinence
Primary: Adverse Events — 223; 7 Number of events
Ventilator Induced Diaphragmatic Dysfunction (VIDD)
Primary: Percent Capture of Left and/or Right Phrenic Nerve — 96.56 percentage of phernic nerve capture — p=0.0125
Diabetes Mellitus, Type 2
Primary: Change in Glycated Hemoglobin — 1.4; 0.9; 1.1 "Percentage of glycated hemoglobin"
Physical Activity
Primary: Schools Who Accepted to Take Part — 3.3 % schools who accepted to take part
Psychosis · First Episode Psychosis · Clinical High Risk for Psychosis
Primary: Duration of Untreated Psychosis
Tissue Tightening
Primary: Investigator Assessment of Improvement — 0.67 score on a scale
Diabetes Mellitus, Type 1
Primary: Severe Hypoglycemia Events — 0; 0; 0 number of events
Urinary Incontinence
Primary: Number of Participants Who Used the ParaPatch System With Adverse Events Through the Completion of the Study — 8; 6 participants
Myopia
Primary: Visual Acuity — -0.038; -0.040 logMAR
Noninvasive Ventilation · Respiratory Insufficiency
Primary: Clinician Assessment of Use With a Questionnaire — 5; 4 units on a scale
Type 1 Diabetes
Primary: Change in A1C From Baseline to Week 15 — -1.7; -1.0 percent glycated hemoglobin
Elder Abuse · Elder Mistreatment
Primary: Participation — 102 Participants
Osteoarthritis
Primary: Feasibility of Data Collection at Month 12 — 55; 48; 5; 9 Participants
Heart Arrhythmia
Primary: Logistics of Study Device Setup and Monitoring — 51; 51; 51; 51 count of participants
Abdominal Aortic Aneurysm
Primary: Primary Safety Endpoint — 0; 0; 0; 1 events
Myopia
Primary: Comfort Throughout the Day - Test Lens vs. Air Optix Aqua Lens — 74.3; 79.4 units on a scale
Tricuspid Valve Regurgitation
Primary: Major Adverse Event Rate : Count and Percentage of Patients Who Experienced at Least One MAE — 10 Participants
Kidney Diseases · Arteriovenous Fistula
Primary: Primary Safety Endpoint — 0 MAES within 30 days post baseline visit
Endometrial Cancer
Primary: Assess Number of Patients Who Were Able to Complete Treatment Delivery Using the Axxent Electronic Brachytherapy System — 15 Participants
Breast Cancer Screening · Oncology · Preventative Medicine
Primary: Change in Total Knowledge Score of Screening Mammography Guidelines — 51.0; 47.0; 56.2; 54.6 score on a scale
Adolescent Drinking · HIV/AIDS · Drug Use
Primary: Percentage of Participants Completing the Study at 6 Months — 44; 46 Participants
Body Fat Disorder
Primary: Change in the Fat Layer of the Treated Area as Measured by Ultrasound The Change in Fat Layer Thickness in the Treated Outer Thigh — -0.25 cm
Alzheimers Disease
Primary: Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers) — 81.7; 88.8; 7.1 Percent Accuracy — p=0.0029
Ventricular Fibrillation
Primary: Defibrillation Threshold (DFT) of the New Shock Electrode Configuration in Joules — 27.0; 31.5 Joules